Ameritas Investment Partners, Inc. Apellis Pharmaceuticals, Inc. Transaction History

Ameritas Investment Partners, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$46.59 - $66.96 $1,537 - $2,209	33 Added 0.45%	7,386 $487,000
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $23,901 - $37,198	534 Added 7.83%	7,353 $502,000
Q2 2022 Aug 12, 2022	BUY	$35.07 - $59.21 $25,566 - $43,164	729 Added 11.97%	6,819 $308,000
Q1 2022 May 13, 2022	BUY	$35.46 - $54.12 $18,084 - $27,601	510 Added 9.14%	6,090 $309,000
Q4 2021 Feb 11, 2022	BUY	$30.74 - $49.16 $16,907 - $27,037	550 Added 10.93%	5,580 $264,000
Q4 2020 Feb 12, 2021	SELL	$30.79 - $57.2 $8,467 - $15,730	-275 Reduced 5.18%	5,030 $288,000
Q2 2020 Aug 05, 2020	BUY	$24.8 - $38.49 $7,216 - $11,200	291 Added 5.8%	5,305 $173,000
Q1 2020 May 13, 2020	BUY	$17.91 - $44.33 $15,653 - $38,744	874 Added 21.11%	5,014 $134,000
Q2 2019 Aug 14, 2019	BUY	$18.0 - $25.34 $18,918 - $26,632	1,051 Added 34.02%	4,140 $105,000
Q2 2018 Aug 13, 2018	BUY	$19.63 - $30.0 $42,577 - $65,070	2,169 Added 235.76%	3,089 $68,000
Q4 2017 Feb 14, 2018	BUY	$12.71 - $21.7 $11,693 - $19,964	920	920 $20,000

300

111M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.